Selectins and monocyte chemotactic peptide as the markers of atherosclerosis activity
Jazyk angličtina Země Česko Médium print
Typ dokumentu klinické zkoušky, časopisecké články, práce podpořená grantem
PubMed
15209534
Knihovny.cz E-zdroje
- MeSH
- arterioskleróza krev diagnóza etiologie terapie MeSH
- biologické markery krev MeSH
- chemokin CCL2 krev MeSH
- hyperlipoproteinemie typ II krev komplikace diagnóza terapie MeSH
- LDL-cholesterol izolace a purifikace MeSH
- lidé MeSH
- reprodukovatelnost výsledků MeSH
- selektiny krev MeSH
- senzitivita a specificita MeSH
- separace krevních složek metody MeSH
- výsledek terapie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- klinické zkoušky MeSH
- práce podpořená grantem MeSH
- Názvy látek
- biologické markery MeSH
- chemokin CCL2 MeSH
- LDL-cholesterol MeSH
- selektiny MeSH
The role of adhesive selectin molecules in the process of atherogenesis is an open question. These molecules are known as markers of atherosclerosis activity, however, only some biological mechanisms are known up to now. In this study we examined the levels of soluble forms of E-, P-selectin and monocyte chemotactic protein (MCP-1) in the process of extracorporeal cholesterol elimination by LDL-apheresis. We measured the levels of sE-, sP-selectin and MCP-1 in the plasma before and after LDL-apheresis and in the washout solution from immunoabsorption columns Lipopak. Eighty measurements were performed repeatedly in 6 patients with severe familial hypercholesterolemia (FH) on long-term LDL-apheresis treatment. Before the procedure P-selectin levels were 204+/-179 ng/ml, E-selectin 32.1+/-33.7 ng/ml, MCP-1 323.8+/-121 pg/l, whereas after the procedure we found P-selectin levels 131.6+/-34 ng/ml, E-selectin 33.1+/-51 ng/ml, and MCP-1 200.4+/-15 pg/l. Levels of P-selectin were increased in the blood of patients with FH in spite of long-term intensive extracorporeal LDL-elimination, documenting thus the activity of atherosclerosis. The levels of P-selectin and MCP-1 decreased significantly after the hypolidemic procedure and could be used as another marker showing the effectivity of the extracorporeal LDL-cholesterol elimination (immediately after the procedure), and, after further verification, may serve as a marker for controlling the therapy efficacy.